Johnson & Johnson
NYSE: JNJ
$147.19
-$1.93 (-1.3%)
Closing Price on June 25, 2024
JNJ Articles
With even moderate appreciation in these five safe Dividend King stocks, growth and income investors should be looking at double-digit total return potential. Given the current turmoil in the...
Published:
With the potential for a sizable correction looming, here are five Dividend Aristocrats that are in sectors that are defensive and that are poised to do well the rest of 2022. With even moderate...
Published:
Analysts at Jefferies have a dividend playbook for the rest of 2022. They consider these eight blue-chip stock picks in a variety of sectors to have "rock solid" dividends that are unlikely to be cut...
Published:
Wednesday afternoon's top analyst upgrades and downgrades included Acadia Pharmaceuticals, Constellation Energy, Edwards Lifesciences, Host Hotels & Resorts, Johnson & Johnson and Magna International.
Published:
With the interest rates about to begin increasing, the Nasdaq close to bear market territory and the market starting to anticipate recession, it may be a good idea for investors to consider these...
Published:
Thursday's top analyst upgrades and downgrades included Abbott Laboratories, Antero Midstream, C3.ai, Equitrans Midstream, Hewlett Packard Enterprise, iQIYI, Johnson & Johnson, Opendoor Technologies,...
Published:
With the potential for a sizable correction looming and interest rates soon headed higher, it might be a good idea for investors to Dividend Aristocrats in sectors that are defensive but look poised...
Published:
Here are previews of four companies, including three Dow components, set to report earnings Tuesday morning.
Published:
Wednesday afternoon's top analyst upgrades and downgrades included Advanced Micro Devices, Analog Devices, Applied Materials, Comcast, Chipotle Mexican Grill, Grab, IBM, Johnson & Johnson, Lyft,...
Published:
Now is the time to reduce risk and more to safer ideas. Top-quality health care stocks may be the way to go for the rest of 2021 and in 2022, and these five Dividend Aristocrats make good sense now...
Published:
These five stay-at-home and pharmaceutical stocks perhaps make sense now, on concerns over the Omicron variant of COVID-19. They are Buy rated and pay solid dividends, and they may be solid ideas as...
Published:
These five incredible blue chip leaders have raised the dividends they pay to shareholders for almost 60 years. The stocks look like great ideas now for worried investors looking for some growth and...
Published:
Here's what to expect when five major companies report earnings next Monday afternoon and Tuesday morning.
Published:
Tuesday’s top analyst upgrades and downgrades included Amgen, Cirrus Logic, Hain Celestial, Johnson & Johnson, Lam Research, Merck, Spotify Technology and Vertex Pharmaceuticals.
Published:
Three Dow Jones industrial average components are reporting June-quarter results before markets open Wednesday.
Published: